

DIRECTORS AND SENIOR MANAGEMENT

OVERVIEW

Our Board consists of six Directors, including three executive Directors and three independent non-executive Directors. All Directors were appointed for a term of three years which is renewable upon re-election. The major powers and functions of the Board include, but are not limited to, convening general meetings, presenting reports to the general meetings, implementing the resolutions passed at the general meetings, determining the operational plans and investment plans of the Group, determining the annual financial budgets and final accounts of the Group, determining the fundamental management systems of the Group and formulating profit distribution plans and loss recovery plans of the Group, and exercising other powers and functions as conferred by the Articles of Association.

DIRECTORS

The following table sets forth the key information about the Directors as at the Latest Practicable Date.

Name	Age	Position	Responsibilities	Date of first appointment	Date of joining the Group
Executive Directors					
Mr. Guo Yang (郭陽)	42	Chairman of the Board, executive Director and general manager	Responsible for overall development strategies, business plans, major operational decisions and overall management of the Group	December 2021	July 2018
Mr. Gao Lifu (高立福)	41	Executive Director and vice general manager	Assist in overall development strategies, business plans, major operational decisions and overall management of the Group	December 2021	July 2018
Ms. Jiang Yujuan (姜玉娟)	58	Executive Director	Assist in overall development strategies, business plans, major operational decisions and overall management of the Group	August 2025	June 2023
Name	Age	Position	Responsibilities	Date of first appointment	Date of joining the Group
Independent non-executive Directors					
Mr. Zhang Wei (張維)	39	Independent non-executive Director	Providing independent advice and judgment to our Board	January 2026	January 2026
Mr. Mei Rongjun (梅榮軍)	65	Independent non-executive Director	Providing independent advice and judgment to our Board	January 2026	January 2026
Dr. Liu Li (劉莉) . .	65	Independent non-executive Director	Providing independent advice and judgment to our Board	January 2026	January 2026

DIRECTORS AND SENIOR MANAGEMENT

Executive Directors

Mr. Guo Yang (郭陽), aged 42, is the chairman of the Board, an executive Director and the general manager of our Company. Mr. Guo Yang founded our Company in July 2018. He was appointed as a director in December 2021 and re-designated as an executive Director of our Company on January 8, 2026. Mr. Guo was also appointed as the Chairman of the Board and the general manager on August 2025.

Mr. Guo Yang has rich experience in the medical and health technology industry. Prior to founding our Group, he served as executive Director and manager at Harbin Huaxin PuJian Medical Technology Co., Ltd. (哈爾濱華新普健醫療科技有限責任公司) from July 13, 2005 to July 30, 2019, where he was responsible for corporate governance and strategic decision-making. He implemented robust training and performance evaluation systems that significantly enhanced organizational efficiency.

In addition, he invested in and established Harbin Huaxin Pujian Traditional Chinese Medicine Research Institute (哈爾濱華新普健中醫藥研究院) from April 27, 2015 to June 29, 2018. During this period, he oversaw the institute’s establishment, including team building and strategic research positioning.

Since founding our Company, Mr. Guo has helped the Company to obtain multiple patents and led the development of over 30 software copyrights, spanning TCM diagnostic and treatment technologies, in-hospital preparations, and digital transformation. He is also the director of the Harbin Association of Chinese Medicine (哈爾濱市中醫學會理事). His rich experience in the medical and health technology industry affords him a profound understanding of industry trends and customer needs, making him qualified to lead the sustained growth of our Company.

Mr. Guo Yang completed a professional education program (專業教學計劃) in relation to medical products business and management (藥品經營與管理) at The Open University of China in July 2024. He has been pursuing a bachelor’s degree in Pharmacy through open education at the same university since September 2024, with expected graduation in January 2027. He is also under a MBA education in China Europe International Business School (中歐國際工商學院) from October 2024 in Shanghai, the PRC, and is expected to graduate in October 2026.

Mr. Gao Lifu (高立福), aged 41, is an executive Director and the vice General Manager of our Company. Mr. Gao joined our Company in July 2018 and was appointed as a vice chairman of the Board December 2021 and deputy general manager of our company in August 2025. Mr. Gao was appointed as a director in December 2021 and was re-designated as an executive Director of our Company on January 8, 2026.

Mr. Gao has an educational background in pharmacy and traditional Chinese medicine, with extensive experience in the biotechnology and pharmaceutical fields. He is familiar with the development logic of the traditional Chinese medicine industry and supply chain management. He is proficient in pharmaceutical management systems, especially in key areas such as quality control of traditional Chinese medicine, production compliance, and supply chain optimization, possessing rich experience. He is capable of coordinating and advancing the standardized operation of the entire pharmaceutical process from raw material control to end-market distribution.

DIRECTORS AND SENIOR MANAGEMENT

From April 2017 to June 2020, he served as general manager of Shenyang Zexuan Biotechnology Co., Ltd (瀋陽澤宣生物技術有限公司).

Mr. Gao obtained an associate degree in pharmacy from China Medical University (中國醫科大學) in PRC in July 2021, via online learning. Since October 2024, he has been pursuing an MBA at China Europe International Business School (中歐國際工商學院) in PRC, with an expected graduation date of October 2026. Mr. Gao also obtained a diploma in traditional Chinese medicine from Liaoning University of Traditional Chinese Medicine (遼寧中醫藥大學) in PRC in January 2025 through correspondence learning.

Ms. Jiang Yujuan (姜玉娟), aged 58, is an executive Director of our Company. Ms. Jiang joined our Company in June 2023 and was appointed as Director in August 2025. She was re-designated as an executive Director of our Company on January 8, 2026.

Ms. Jiang has extensive experience in the Chinese medicine industry. From July 1989 to February 2017, she worked at the Second Chinese Medicine Factory of Harbin Pharmaceutical Group (哈藥集團中藥二廠). During this period, she served as a Researcher in the Chinese Medicine Research Institute, focusing on new product research and development; as the Workshop Director of the Powder Injection Preparation Workshop, fully in charge of the daily production arrangement and management of the workshop; and as the Minister of the Production Technology Department, fully responsible for the production management of all production workshops of the enterprise, establishing, maintaining and improving the process and quality management system, and responsible for process and quality management. From March 2017 to December 2022, she worked at Harbin Pharmaceutical Group Chinese Medicine Co., Ltd. (哈藥集團中藥有限公司), where she served as the Minister of the Operation Planning Department, fully responsible for the enterprise operation management and planning management, and as the Deputy General Manager of the General Manager’s Office, responsible for the management of the company’s production, technology, warehousing and logistics, equipment and energy power, procurement and other departments.

Ms. Jiang obtained a bachelor’s degree in Science (with a major in Chinese Medicine) from Heilongjiang College of Chinese Medicine (黑龍江中醫學院)(currently known as Heilongjiang University of Chinese Medicine (黑龍江中醫藥大學)) in Heilongjiang, the PRC, in July 1989.

Independent non-executive Directors

Mr. Zhang Wei (張維), aged 39, was appointed as our independent non-executive Director on January 8, 2026 with effect [REDACTED]. He is primarily responsible for providing independent advice and judgment to our Board.

Mr. Zhang has over 15 years of experience in the finance and audit industry. Mr. Zhang’s audit related experience includes working as an auditor at Deloitte & Touche LLP from September 2008 to September 2011 and as an audit manager of KPMG from October 2011 to December 2015. Mr. Zhang has previously worked as a finance manager at CMC Capital Partners HK Limited, and he has also served as a senior finance manager at Asia-Germany Industrial Promotion Limited since June 2017, as the vice president at Lunar Capital Management Limited since April 2020, as the director of fund services at ICS Corporate Services since June 2021, and as the current managing director and member of ICS CPA Limited.

Mr. Zhang has been registered as a certified public accountant with the Board of Accountancy of the Department of Professional and Financial Regulation Office of Professional and Occupational Regulation of the State of Maine in the United States since October 2020 and has also been registered as a certified public accountant with the Hong Kong Institute of Certified Public Accountants since March 2021. Mr. Zhang is a certified anti-money laundering specialist, the certification of which was awarded

DIRECTORS AND SENIOR MANAGEMENT

by the Association of Certified Anti-Money Laundering Specialist in March 2020. Mr. Zhang obtained a bachelor of science in business administration and accounting and corporate finance from San Francisco State University in the United States in May 2008.

Mr. Mei Rongjun (梅榮軍), aged 65, was appointed as our independent non-executive Director on January 8, 2026 with effect [REDACTED]. He is primarily responsible for providing independent advice and judgment to our Board.

Mr. Mei has extensive experience in the Chinese medicine industry. Mr. Mei has been engaged in the tuina profession since 1983, focusing on the clinical diagnosis and treatment of patients with cervical spondylotic radiculopathy for a long time. In clinical practice, he inherited the experienced techniques from professional predecessors and integrated various tuina manipulations and technologies to develop the standardized rotational mobilization method for cervical spondylotic radiculopathy (頸椎病神經根型旋轉鬆動法規範), which won the Third Prize of Scientific and Technological Achievements of Heilongjiang Provincial Government (黑龍江省政府科技成果三等獎). He then conducted innovative research on the cervical rotational mobilization method (頸椎旋轉鬆動法) for 12 years, winning the First Prize of TCM Appropriate Technology (中醫適宜技術一等獎) from Heilongjiang Administration of Traditional Chinese Medicine in 2020. Throughout his career, he has been awarded 1 Third Prize of Provincial Government Scientific and Technological Progress (省政府科技進步三等獎), 1 First Prize of Provincial TCM Science and Technology Award (省中醫藥科學技術獎一等獎), and 1 First Prize of Provincial Administration of TCM New Technology Application Award (省中醫局中醫新技術應用一等獎). He has published more than 30 academic papers and 7 monographs, including 2 auxiliary textbooks for national unified planning textbooks (國家級統編規劃教材輔助教材) as chief editor and 5 national unified textbooks as deputy chief editor.

Mr. Mei obtained a bachelor’s degree with a major in Chinese Medicine from Heilongjiang College of Chinese Medicine (黑龍江中醫學院)(currently known as Heilongjiang University of Chinese Medicine (黑龍江中醫藥大學)) in Heilongjiang, the PRC, in July 1983.

Dr. Liu Li (劉莉), aged 65, was appointed as our independent non-executive Director on January 8, 2026 with effect [REDACTED]. She is primarily responsible for providing independent advice and judgment to our Board.

Dr. Liu is a seasoned expert in the field of TCM cardiovascular diseases. She currently serves as Director of the First Department of Cardiovascular Diseases at The First Affiliated Hospital of Heilongjiang University of Chinese Medicine (黑龍江中醫藥大學附屬第一醫院). Ms. Liu has taken the lead in more than 10 key research projects, including those funded by the National Natural Science Foundation of China (國家自然科學基金). Her research achievements have been widely recognized, earning her 2 Second Prizes of Provincial Government Scientific and Technological Progress (省政府科技進步二等獎).

Dr. Liu obtained a bachelor’s degree with a major in Chinese Medicine from Heilongjiang College of Chinese Medicine (黑龍江中醫學院)(currently known as Heilongjiang University of Chinese Medicine (黑龍江中醫藥大學)) in Heilongjiang, PRC, in December 1982. Dr. Liu obtained a Master’s degree with a major in Chinese Medicine in June 1988 and obtained a doctoral degree in the same school.

DIRECTORS AND SENIOR MANAGEMENT

SENIOR MANAGEMENT

The following table sets forth the key information about the senior management as at the Latest Practicable Date.

Name	Age	Position	Responsibilities	Date of first appointment	Date of joining the Group
Mr. Guo Yang (郭陽)	42	Chairman of the Board, executive Director and general manager	Responsible for overall development strategies, business plans, major operational decisions and overall management of the Group	July 2018	July 2018
Mr. Gao Lifu (高立福)	41	Executive Director and deputy general manager	Assist in overall development strategies, business plans, major operational decisions and overall management of the Group	July 2018	July 2018
Mr. Yan Haitao (閆海濤)	47	Chief financial officer	Responsible for overseeing the financial operations and strategies of our Group	January 2021	January 2021

For information concerning Mr. Guo Yang and Mr. Gao see “— Directors — Executive Directors.”

Mr. Yan Haitao (閆海濤), aged 47, is the chief financial officer of our Company.

Mr. Yan has extensive experience in management. From September 2010 to June 2019, he worked at Harbin Hanlin Tianyue Hotel Co., Ltd. (哈爾濱翰林天悅大酒店有限公司). During this period, from September 2010 to July 2017, he served as the deputy general manager and chief financial officer, overseeing finance, human resources, engineering, and procurement. From August 2017 to June 2019, he acted as the general manager, taking charge of all-round operations. From July 2019 to November 2020, he served as the General Manager at Harbin Longda Ruiji Business Hotel (哈爾濱龍達瑞吉商務酒店), responsible for the overall management of the hotel. Mr. Yan joined our Group in January 2021 as a chief financial officer and board secretary since then. Mr. Yan is a International Certified Public Accountant (國際註冊會計師), and qualified as a senior accountant (高級會計師) in the PRC.

Mr. Yan obtained a bachelor’s degree in Accounting through online education from Northeast Agricultural University (東北農業大學) in Heilongjiang, the PRC, in July 2022.

INTERESTS OF DIRECTORS AND SENIOR MANAGEMENT

Saved as disclosed above, to the best of the knowledge, information and belief of our Directors having made all reasonable enquiries, as of the Latest Practicable Date, none of our Directors and senior management had been a director of any public company the securities of which were listed on any securities market in Hong Kong or overseas in the three years immediately preceding the date of this Document. There are no other matters with respect to the appointment of our Directors that need to be brought to the attention of the Shareholders, nor is there any information relating to our Directors that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

Saved as disclosed above, as of the Latest Practicable Date, none of our Directors or senior management were related to other Directors or senior management of our Company.

DIRECTORS AND SENIOR MANAGEMENT

Saved as disclosed in the sections headed “Relationship with our Controlling Shareholders,” “Substantial Shareholders” and “Appendix IV — Statutory and General Information — 4. Disclosure of Interests — A. Disclosure of Interests of Directors,” as of the Latest Practicable Date, none of our Directors held any interest in the securities within the meaning of Part XV of the SFO.

JOINT COMPANY SECRETARIES

Mr. Yan Haitao (閻海濤) was appointed as our joint company secretary. For details of his biography, see “Senior Management” in this section.

Ms. Lam Wing Chi (林穎芝) has been appointed as a joint company secretary of our Company effective upon [REDACTED].

Ms. Lam is a Director of Corporate Secretarial Services of InCorp Hong Kong. Ms. Lam has over 12 years of experience in the corporate secretarial and compliance work. She has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Lam is a Chartered Secretary, a Chartered Governance Professional and an Associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Ms. Lam received her bachelor’s degree in Accounting from the Hong Kong Shue Yan University.

CONFIRMATION FROM OUR DIRECTORS

Rule 8.10 of the Listing Rules

Each of our Directors confirms that as of the Latest Practicable Date, he or she did not have any interest in a business which competes or is likely to compete, either directly or indirectly, with our Company’s business which would require disclosure under Rule 8.10 of the Listing Rules.

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules on February 26, 2025 and (ii) understands the requirements under the Listing Rules that are applicable to him or her as a director of a listed issuer under the Listing Rules and the possible consequences of making a false declaration or giving false information to the Stock Exchange.

Rule 3.13 of the Listing Rules

Each of the independent non-executive Directors has confirmed (i) his/her independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules, (ii) that he/she had no past or present financial or other interests in the business of the Company or its subsidiaries or any connection with any core connected person of the Company under the Listing Rules as of the Latest Practicable Date and (iii) that there were no other factors that may affect his/her independence at the time of his/her appointment.

BOARD COMMITTEES

Our Board delegates certain responsibilities to various committees. In accordance with the relevant PRC laws and regulations and the Corporate Governance Code and the Listing Rules, our Company has formed three Board committees, namely the Audit Committee, the Remuneration and Appraisal Committee and the Nomination Committee.

DIRECTORS AND SENIOR MANAGEMENT

Audit Committee

We have resolved to establish an Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The Audit Committee consists of three Directors, namely Mr. Zhang Wei, Ms. Liu Li and Mr. Mei Rongjun. Mr. Zhang Wei, being the chairperson of the Audit Committee, holds the appropriate professional qualifications as required under Rules 3.10(2) and 3.21 of the Listing Rules. The primary duties of the Audit Committee include, but are not limited to, the following:

- reviewing and evaluating the work of external auditors;
- monitoring and making recommendations concerning the internal audit work of our Company;
- reviewing and making recommendations concerning the financial reports of our Company;
- evaluating the effectiveness of internal control work;
- ensuring coordination between the management, internal audit department and relevant departments and external auditors; and
- performing other duties and responsibilities as assigned by our Board.

Remuneration Committee

We have resolved to establish a Remuneration Committee with written terms of reference in compliance with the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The Remuneration Committee consists of three Directors, namely Ms. Liu Li, Mr. Mei Rongjun and Mr. Guo Yang. Ms. Liu Li serves as the chairperson of the Remuneration and Appraisal Committee. The primary duties of the Remuneration and Appraisal Committee include, but are not limited to, the following:

- reviewing and approving remuneration proposals of members of our senior management in accordance with our Company’s policies and objectives as approved by our Board from time to time;
- making recommendations to our Board concerning our Company’s policy and structure for all Directors’ and senior management remuneration and on the establishment of a formal and transparent procedure for developing remuneration policy, including, but not limited to, performance evaluation standards, procedures and evaluation systems;
- conducting the evaluation of the annual performance of all Directors and senior management;
- monitoring remuneration payable to all Directors and senior management;
- reviewing and/or approving matters relating to share schemes under Chapter 17 of the Listing Rules; and
- performing other duties and responsibilities as assigned by our Board.

Nomination Committee

We have resolved to establish a Nomination Committee with written terms of reference in compliance with the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The Nomination Committee consists of three Directors, namely Mr. Guo Yang, Ms. Liu Li and Mr. Mei Rongjun. Mr. Guo Yang serves as the chairperson of the Nomination Committee. The primary duties of the Nomination Committee include, but are not limited to, the following:

- reviewing and making recommendations to the Board on the composition and number of our Board and senior management with reference to our Company’s business activities, the scale of assets and shareholding structure;
- identifying individuals suitably qualified to become a member of our Board and senior management, and making recommendations to our Board on the selection of individuals nominated for directorships and senior management;

DIRECTORS AND SENIOR MANAGEMENT

- reviewing the structure and diversity of the Board and selecting individuals to be nominated as Directors;
- accessing and making recommendations to the selection of other senior management appointed by our Board; and
- performing other duties and responsibilities as assigned by our Board.

BOARD DIVERSITY

Our Company has adopted the board diversity policy which sets out the objective and approach for achieving and maintaining diversity of the Board in order to enhance its effectiveness. In accordance with the board diversity policy, our Company seeks to achieve board diversity by taking into account a number of factors, including but not limited to gender, age, cultural and educational background, professional experience, skills, knowledge and/or length of service.

The Board currently consists of four male and two female members, with three executive Directors and three independent non-executive Directors of ages ranging from 39 to 65 with diversified backgrounds and experience. We consider that our Board has a balanced mix of skill set, experience, expertise, and diversity which enhances decision-making capability and the overall effectiveness of the Board in achieving sustainable business operation and enhancing shareholder value. In recognition of the importance of gender diversity, our Company has taken, and will continue to take steps to promote gender diversity in the Board. Our Company will continue to consider increasing the proportion of female Board members over time when selecting suitable new or additional candidates for appointments to the Board so as to ensure that appropriate gender diversity is achieved.

Upon the [REDACTED], the Nomination Committee will from time to time (i) assess and review expected goals to ensure board diversity and (ii) review and, where necessary, update the board diversity policy to ensure that the policy remains effective. Our Company will disclose the biographical details of each Director and report on the implementation of the board diversity policy (including whether our Company has achieved board diversity) in its annual corporate governance report.

CORPORATE GOVERNANCE

Our Company is committed to achieving high standards of corporate governance with a view to safeguarding the interests of our shareholders. To accomplish this, our Company intends to comply with the Corporate Governance Code set out in Appendix C1 to the Listing Rules and the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules after [REDACTED].

Pursuant to code provision C.2.1 of the Corporate Governance Code, companies listed on the Stock Exchange are expected to comply with, but may choose to deviate from the requirement that the responsibilities between the Chairman and the Chief Executive Officer/general manager should be segregated and should not be performed by the same individual. We do not have a separate Chairman and Chief Executive Officer/general manager, and Mr. Guo Yang currently performs these two roles. The Board believes that vesting the roles of both the Chairman and Chief Executive Officer/general manager in the same person has the benefit of ensuring consistent leadership within our Group and enables more effective and efficient overall strategic planning and implementation of our Board's decisions for our Group. Our Board considers that the balance of power and authority for the present arrangement will not be impaired and this structure will enable our Company to make and implement decisions promptly and effectively. Our Board will continue to review and consider splitting the roles of the chairman of our Board and the Chief Executive Officer/general manager of our Company if and when it is appropriate taking into account the circumstances of our Group as a whole.

DIRECTORS AND SENIOR MANAGEMENT

Save as disclosed above, our Company intends to comply with all code provisions under the Corporate Governance Code after [REDACTED].

REMUNERATION OF OUR DIRECTORS AND SENIOR MANAGEMENT, AND REMUNERATION OF THE FIVE HIGHEST-PAID INDIVIDUALS

The Directors and senior management members who receive remuneration from the Company are paid in the forms of salaries and other benefits in kind, discretionary bonuses, retirement benefit scheme contributions and share-based payment. The remuneration of the Directors and senior management members is determined with reference to the remuneration paid by comparable companies and the achievement of major operating indicators of the Company.

For the years ended December 31, 2023, 2024 and 2025, and the five months ended May 31, 2026, the aggregate amount of remuneration paid or payable to our Directors and supervisors amounted to approximately RMB1,114,000, RMB1,709,000, RMB4,262,000 and RMB2,009,000 respectively.

The aggregate amount of remuneration (including salaries and other benefits in kind, discretionary bonuses, retirement benefit scheme contributions and share-based payment) and other benefits in kind incurred by the five highest-paid individuals (including nil, 2 and 2 Directors, respectively) of the Group for the years ended December 31, 2023, 2024 and 2025, and the five months ended May 31, 2026, amounted to RMB2,817,000, RMB1,852,000, RMB7,248,000 and RMB2,046,000 respectively.

We offer our executive Directors and senior management members, who are also the Company’s employees, remuneration in the form of salaries, allowances and benefits in kind, performance related bonuses and pension scheme contributions. Our independent non-executive Directors receive remuneration with reference to their respective positions and duties, including being a member or the chairperson of Board committees.

Under the arrangement currently in force, we estimate the total remuneration before taxation, to be accrued to our Directors for the year ended December 31, 2026 to be approximately RMB3,196,929.

We confirmed that during the Track Record Period, no remuneration was paid by our Company to, or receivable by, our Directors, Supervisors or the five highest paid individuals as an inducement to join or upon joining our Company or as compensation for loss of office in connection with the management positions of any subsidiary of our Company. During the Track Record Period, none of our Directors or Supervisors waived any remuneration. Save as disclosed above, no other payments have been paid, or are payable, by our Company or any of our subsidiaries to our Directors, Supervisors or the five highest paid individuals during the Track Record Period.

COMPLIANCE ADVISER

The Company has appointed Guoyuan Capital (Hong Kong) Limited as our Compliance Adviser in compliance with Rule 3A.19 of the Listing Rules. The Compliance Adviser will provide us with guidance and advice as to compliance with the Listing Rules and other applicable laws, rules, codes and guidelines. Pursuant to Rule 3A.23 of the Listing Rules, the Compliance Adviser will advise the Company in certain circumstances including:

- (i) before the publication of any regulatory announcement, circular or financial report;
- (ii) where a transaction, which might be a notifiable or connected transaction, is contemplated, including share issues and share repurchases;
- (iii) where we propose to [REDACTED] from the [REDACTED] in a manner different from that detailed in this document or where our business activities, developments or results deviate from any forecast, estimate or other information in this document; and

DIRECTORS AND SENIOR MANAGEMENT

- (iv) where the Stock Exchange makes an inquiry to the Company in accordance with Rule 13.10 of the Listing Rules.

Pursuant to Rule 3A.24 of the Listing Rules, the Compliance Adviser will, on a timely basis, inform the Company of any amendment or supplement to the Listing Rules that are announced by the Stock Exchange. The Compliance Adviser will also inform the Company of any new or amended law, regulation or code in Hong Kong applicable to us, and advise us on the continuing requirements under the Listing Rules and applicable laws and regulations.

The term of the appointment will commence on [REDACTED] and is expected to end on the date on which the Company complies with Rule 13.46 of the Listing Rules in respect of our financial results for the first full financial year commencing after [REDACTED].